George D Demetri
George D Demetri is an expert in Oncology at Dana-Farber Cancer Institute (United States). As of June 2026, ScienceLeadR ranks George D Demetri in the top 1% of experts worldwide for Sarcoma and Gastrointestinal Neoplasms. George D Demetri has authored 611 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 2 of them ongoing. SLR score: 2,773 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Biochemistry - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1986 - 2026
Number : 611
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial. PMID 42191879 — confidence intervals, growth, gastrointestinal stromal tumors, oxidoreductases, succinate dehydrogenase, molecular biology, neoplasms, biopsy, receptors, growth factor, receptors, fibroblast growth factor, fibroblasts, exome, fibroblast growth factors | Nat Med Top journal | 2026 | 0 |
| Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study. PMID 41882006 — sarcoma, synovial, biological science disciplines, neoplasms, rhabdoid tumor, sarcoma, chordoma, therapeutics | Nat Commun | 2026 | 0 |
| Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. PMID 41564157 — glucagon-like peptide 1, cells, cell plasticity, liposarcoma, neoplasms, histology | Sci Transl Med | 2026 | 0 |
| A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE). PMID 41481257 — hemangiosarcoma, hemangioendothelioma, neoplasms, sarcoma, therapeutics, hemangioendothelioma, epithelioid | Clin Cancer Res | 2026 | 0 |
| Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. PMID 40596693 — blood, transcriptome, neoplasms, multiple chronic conditions, biopsy, machine learning, exome, therapeutics, learning, artificial intelligence, tissues, liquid biopsy | Sci Rep | 2025 | 0 |
Clinical Studies 41
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) NCT06088290 — leiomyosarcoma, doxorubicin, neoplasms, therapeutics | Phase 3 | Active not recruiting | 2023 |
| Testing the Anti cancer Drug Rogaratinib (BAY 1163877) for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1 4) and in Patients With SDH deficient Gastrointestinal Stromal Tumor (GIST) NCT04595747 — cells, research design, growth, blood, gastrointestinal stromal tumors, pharmaceutical preparations, tomography, positron-emission tomography, neoplasms, magnetic resonance imaging, biopsy, positron emission tomography computed tomography, sarcoma, receptors, growth factor, receptors, fibroblast growth factor, specimen handling, fibroblasts, therapeutics, fibroblast growth factors | Phase 2 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map